Business
Medicure Announces Positive Settlement of Product Development and Supply Contracts
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. (" Medicure " or the " Company ") (...
About this update from Medicure Inc.
[{"type":"text","content":"Medicure Announces Positive Settlement of Product Development and Supply ContractsWINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that a product development and supply contract settlement between its subsidiaries Medicure International Inc. & Medicure Pharma Inc., and a third party has been reached.Medicure has received a payment of € 1.5 million as final settlement. All other terms of the settlement along with the name of the party involved remain confidential.About Medicure Inc.Medicure is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (\"Marley Drug\"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected]. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastathdb.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.To be added to Medicure's e-mail list, please visit: http://medicure.mediaroom.com/alertsNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forwar...